225 related articles for article (PubMed ID: 17570091)
1. [Diabetology 2007].
Scherbaum WA
Dtsch Med Wochenschr; 2007 Jun; 132(25-26):1407-10. PubMed ID: 17570091
[No Abstract] [Full Text] [Related]
2. [Obesity and cardiovascular morbidity].
Berg A; Bönner G
Dtsch Med Wochenschr; 2005 Apr; 130(14):893-7. PubMed ID: 15800824
[No Abstract] [Full Text] [Related]
3. Unmet needs in controlling metabolic disease.
Haffner SM
Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
[TBL] [Abstract][Full Text] [Related]
4. Early screening for diabetes mellitus: has it been overstated?
Boucher FG
Can Fam Physician; 2004 Nov; 50():1503-4. PubMed ID: 15597968
[No Abstract] [Full Text] [Related]
5. [Clinical advances in diabetes].
Martin S; Scherbaum WA
Dtsch Med Wochenschr; 2006 Jun; 131(25-26):1461-2. PubMed ID: 16794976
[No Abstract] [Full Text] [Related]
6. Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors.
Harris SB; Lank CN
Can Fam Physician; 2004 Mar; 50():425-33. PubMed ID: 15318682
[No Abstract] [Full Text] [Related]
7. Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?
Krantz MJ
Pharmacotherapy; 2006 Jul; 26(7):1049; discussion 1049-50. PubMed ID: 16803430
[No Abstract] [Full Text] [Related]
8. [Time for a European perspective on cardiovascular prevention].
Nilsson PM; Perk J; Rydén L
Lakartidningen; 2008 Apr 2-8; 105(14):1000-4. PubMed ID: 18478749
[No Abstract] [Full Text] [Related]
9. Diabetes as a 'cardiovascular disease equivalent': implications for treatment.
Laakso M
Nat Clin Pract Cardiovasc Med; 2008 Nov; 5(11):682-3. PubMed ID: 18797431
[TBL] [Abstract][Full Text] [Related]
10. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
Sacks FM
Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
[No Abstract] [Full Text] [Related]
11. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
Marx N
Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
[No Abstract] [Full Text] [Related]
12. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
Martin S
Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
[No Abstract] [Full Text] [Related]
13. STOP-NIDDM: a new paradigm for diabetes prevention?
Hanefeld M
Nutr Metab Cardiovasc Dis; 2002 Oct; 12(5):253-8. PubMed ID: 12616804
[No Abstract] [Full Text] [Related]
14. Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist.
Wikström G; Malmberg K; Rydén L
Eur Heart J; 1999 Mar; 20(6):403-5. PubMed ID: 10213343
[No Abstract] [Full Text] [Related]
15. A practical approach to reducing cardiovascular risk factors.
Fonarow GC
Rev Cardiovasc Med; 2007; 8 Suppl 4():S25-36. PubMed ID: 17934391
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.
Kadoglou NP; Iliadis F; Liapis CD; Perrea D; Angelopoulou N; Alevizos M
Diabetes Care; 2007 Sep; 30(9):2242-4. PubMed ID: 17586747
[No Abstract] [Full Text] [Related]
17. Does intensive glycemic control improve cardiovascular outcomes?
Pendergrass M
Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
[No Abstract] [Full Text] [Related]
18. New insights into understanding cardiometabolic risk. Introduction.
Fonarow GC; Watson KE
Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389
[No Abstract] [Full Text] [Related]
19. Use of exenatide for weight loss in patients with diabetes.
Virji A
Am Fam Physician; 2007 May; 75(9):1304. PubMed ID: 17511061
[No Abstract] [Full Text] [Related]
20. [Cardioprotection by acarbose--contra].
Kaiser T; Sawicki PT
Dtsch Med Wochenschr; 2004 May; 129(20):1156. PubMed ID: 15143460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
